Increasing number of components of the metabolic syndrome and cardiac structural and functional abnormalities – cross-sectional study of the general population by Azevedo, Ana et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Cardiovascular Disorders
Open Access Research article
Increasing number of components of the metabolic syndrome and 
cardiac structural and functional abnormalities – cross-sectional 
study of the general population
Ana Azevedo*1,2, Paulo Bettencourt2, Pedro B Almeida3, Ana C Santos1, 
Cassiano Abreu-Lima3, Hans-Werner Hense4 and Henrique Barros1
Address: 1Department of Hygiene and Epidemiology, University of Porto Medical School, Porto, Portugal, 2Department of Internal Medicine, 
Hospital de S. João and University of Porto Medical School, Porto, Portugal, 3Department of Cardiology, University of Porto Medical School, 
Porto, Portugal and 4Institute of Epidemiology and Social Medicine, University of Muenster, Muenster, Germany
Email: Ana Azevedo* - anazev@med.up.pt; Paulo Bettencourt - pbettfer@claranet.pt; Pedro B Almeida - pbalmeida@yahoo.com; 
Ana C Santos - acsantos@med.up.pt; Cassiano Abreu-Lima - cassal@hsjoao.min-saude.pt; Hans-Werner Hense - hense@uni-muenster.de; 
Henrique Barros - hbarros@med.up.pt
* Corresponding author    
Abstract
Background: We aimed to assess whether we could identify a graded association between increasing
number of components of the metabolic syndrome and cardiac structural and functional abnormalities
independently of predicted risk of coronary heart disease by the Framingham risk score.
Methods: We conducted a cross-sectional study on a random sample of the urban population of Porto
aged 45 years or over. Six hundred and eighty-four participants were included. Data were collected by a
structured clinical interview with a physician, ECG and a transthoracic M-mode and 2D echocardiogram.
The metabolic syndrome was defined according to ATPIII-NCEP. The association between the number of
features of the metabolic syndrome and the cardiac structural and functional abnormalities was assessed
by 3 multivariate regression models: adjusting for age and gender, adjusting for the 10-year predicted risk
of coronary heart disease by Framingham risk score and adjusting for age, gender and systolic blood
pressure.
Results: There was a positive association between the number of features of metabolic syndrome and
parameters of cardiac structure and function, with a consistent and statistically significant trend for all
cardiac variables considered when adjusting for age and gender. Parameters of left ventricular geometry
patterns, left atrial diameter and diastolic dysfunction maintained this trend when taking into account the
10-year predicted risk of coronary heart disease by the Framingham score as an independent variable,
while left ventricular systolic dysfunction did not. The prevalence of left ventricular diastolic dysfunction,
and the mean left ventricular mass, left ventricular diameter and left atrial diameter increased significantly
with the number of features of the metabolic syndrome when additionally adjusting for systolic blood
pressure as a continuous variable.
Conclusion: Increasing severity of metabolic syndrome was associated with increasingly compromised
structure and function of the heart. This association was independent of Framingham risk score for indirect
indices of diastolic dysfunction but not systolic dysfunction, and was not explained by blood pressure level.
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Background
The metabolic syndrome is associated with an increased
risk of coronary heart disease [1] which in turn is one of
the major causes of heart failure and left ventricular systo-
lic and diastolic dysfunction. Furthermore, hypertension,
obesity, and diabetes mellitus have been shown to be
independently associated with an increased risk of heart
failure, regardless of coronary heart disease [2-8]. There-
fore, an association between the presence of the metabolic
syndrome and the occurrence of different stages of heart
failure seems plausible.
Given the increasing prevalence of heart failure and its
consequences – impaired quality of life [9], frequent hos-
pital admissions and high case fatality rate [10] – it
appears of importance to assess how its occurrence is asso-
ciated with the highly prevalent [11] metabolic syndrome.
We conceptualise a potential causal pathway for this asso-
ciation in which increasing severity of the metabolic syn-
drome, quantified as increasing concurrence of its single
components, leads to increasingly compromised structure
and function of the heart.
There has been much debate about the putative usefulness
of the metabolic syndrome in cardiovascular risk predic-
tion, namely whether it adds information to that provided
by its individual components and, on the other hand,
whether it adds to alternative risk prediction tools [12-
14], among which the Framingham risk score [15] is the
most widely used.
The aim of this study was therefore to assess whether we
could identify a graded association between increasing
number of components of the metabolic syndrome and
cardiac structural and functional abnormalities in a cross-
sectional study of urban Portuguese adults. Additionally,
we intended to investigate whether this association was
independent of predicted risk of coronary heart disease by
the Framingham risk score.
Methods
As part of a health and nutrition survey of a representative
sample of the adult population of Porto, Portugal, all par-
ticipants aged ≥ 45 years and recruited from January 2001
to December 2003 were assessed with a systematic evalu-
ation of parameters of cardiac structure and function. A
detailed description of the study has been published [16].
In brief, random digit dialling was used to select house-
holds followed by simple random sampling to select one
subjects aged ≥ 18 years within each household Refusals
were not substituted. The proportion of participation was
70% [17]. The local ethics committee approved the study
and participants provided written informed consent.
Participants were invited to visit our Department for an
interview, which included questionnaires on demo-
graphic, behavioural and clinical data. After a 12-hour
fast, a venous blood sample was collected. Serum glucose
level was determined using routine enzymatic methods,
and cholesterol and triglyceride levels were determined
using standard enzymatic colorimetric methods [18,19].
HDL cholesterol levels were determined after precipita-
tion of apolipoprotein B-containing lipoproteins [20].
Anthropometric evaluation included waist circumference
measurement to the nearest centimeter, midway between
the lower limit of the rib cage and the iliac crest, with the
subject standing using a flexible and non-distensible tape
[21]. A spirometry and a resting 12-lead ECG were per-
formed. Ischemic heart disease was defined as self-
reported medical diagnosis of angina pectoris or myocar-
dial infarction or pathologic Q waves on at least two adja-
cent leads on resting 12-lead ECG. Chronic lung disease
was defined as history of chronic bronchitis or a diagnosis
of moderate-severe obstructive (FEV1 < 70% of predicted)
or restrictive (vital capacity < 70% of predicted) syndrome
on spirometry. A few days after the first interview, a struc-
tured clinical interview by a physician, a cardiovascular
physical examination and a transthoracic echocardiogram
with pulsed Doppler evaluation of transmitral inflow
were performed. Hypertension was defined as blood pres-
sure ≥ 140/90 mmHg or being under anti-hypertensive
medication. Blood pressure was measured after a 10-
minute rest, with no tight clothes. The mean of two meas-
urements was registered. Diabetes mellitus was consid-
ered as self-reported or fasting venous blood glucose ≥
126 mg/dl [22]. Participants who were under antihyper-
tensive or antidiabetic medications were considered to
have high blood pressure or high glucose levels, regardless
of current blood pressure or serum glucose [23,24]. The
predicted 10-year risk of coronary heart disease was calcu-
lated for participants aged less than 75 years who had no
coronary heart disease, according to the Framingham
Heart Study risk prediction score using risk factor catego-
ries [15]. Models based on LDL cholesterol were used.
Echocardiograms were done by four cardiologists, using
the same equipment (HP Sonos 5500) and recorded on
videotape for later review by a single experienced cardiol-
ogist (C.A.L.), blinded to clinical data. Measurements of
wall thicknesses and chamber dimensions were obtained
according to the Penn convention and left ventricular
mass was calculated as 1.04 [(interventricular septum
thickness + LV end-diastolic diameter + posterior wall
thickness)3 - (LV end-diastolic diameter)3] - 13.6 [25]. Left
ventricular mass, wall thicknesses and chamber diameters
were indexed to height. Left ventricular mass was also
indexed to height2.7 and fat-free mass, estimated accord-
ing to the equations reported by Kuch et al [26] using
height and weight, in order to assess whether alternativeBMC Cardiovascular Disorders 2007, 7:17 http://www.biomedcentral.com/1471-2261/7/17
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indexation methods influenced the results. Left ventricu-
lar (LV) systolic function was assessed by the subjective
impression of the operating cardiologist later validated by
one single experienced cardiologist. Left ventricular ejec-
tion fraction was estimated by Simpson's rule. Left ven-
tricular systolic dysfunction (LVSD) was defined as either
ejection fraction < 45% or by eyeballing, this being the
only parameter when ejection fraction could not be calcu-
lated (44 participants). In participants in sinus rhythm,
the peak E wave/peak A wave ratio (E/A), E wave deceler-
ation time (DT) and isovolumetric relaxation time (IVRT)
were used to define the presence of diastolic dysfunction
according to the European Society of Cardiology [27]:
IVRT > 100 ms and/or E/A < 1.0 and DT > 220 ms if aged
< 50 years; IVRT > 105 ms and/or E/A < 0.5 and DT > 280
ms if aged = 50 years.
Participants were classified according to the stages of heart
failure defined by the American College of Cardiology
and American Heart Association [28]: Stage A – high risk
of heart failure, including hypertension, diabetes mellitus,
metabolic syndrome, coronary heart disease, smoking,
excessive alcohol intake; Stage B – asymptomatic heart
disease, including left ventricular systolic dysfunction, left
ventricular dilatation, moderate-severe valvular heart dis-
ease and left ventricular hypertrophy; Stage C – sympto-
matic heart failure, including heart failure symptoms or
signs plus any of the abnormalities described in stage B,
with the exception of left ventricular hypertrophy which
was considered to be responsible for those symptoms
only in the absence of chronic lung disease. Dyspnoea,
orthopnoea, nocturnal paroxysmal dyspnoea, evening
lower limb oedema, jugular venous distension and rales
were considered related to heart failure when at least two
of them were present. Lower limb oedema was disre-
garded if there were signs of chronic venous insufficiency.
Features of the metabolic syndrome were defined accord-
ing to the Adult Treatment Panel III of the National Cho-
lesterol Education Program (ATPIII-NCEP) [23]:
1. Waist circumference > 102 cm in men and > 88 cm in
women;
2. Fasting serum triglycerides ≥ 150 mg/dl;
3. High-density lipoprotein (HDL) cholesterol < 40 mg/dl
in men and < 50 mg/dl in women;
4. High blood pressure: systolic blood pressure ≥ 130
mmHg and/or diastolic blood pressure ≥ 85 mmHg or
antihypertensive drug treatment;
5. High glucose levels: fasting serum glucose ≥ 110 mg/dl
or clinical diagnosis of diabetes.
Statistical analysis
Due to missing data on key variables for the definition of
the metabolic syndrome (5 missing waist circumference,
37 triglyceride levels, 39 HDL cholesterol levels, 31 glu-
cose levels), only 684 participants were available for anal-
ysis.
Data are described as mean and standard deviation for
normally, or as median and corresponding 25th and 75th
centiles for clearly non-normally distributed variables.
Counts and proportions are reported for categorical varia-
bles. We studied cardiac structural and functional abnor-
malities among participants according to the number of
components of the metabolic syndrome. The association
between the degree of the metabolic syndrome and car-
diac structural and functional abnormalities was assessed
by calculating mean values of the dependent cardiac vari-
ables by linear regression, adjusting first for age and gen-
der, then for 10-year predicted risk of coronary heart
disease by Framingham risk score (continuous variable)
and finally for age, gender and systolic blood pressure,
considering that the reported association might be
explained by increasingly high blood pressure. Likewise,
adjusted proportions of categorised cardiac variables were
estimated using logistic regression by applying popula-
tion averages of the cofactors to the regression coefficients
derived in the regression model. To analyze a graded
effect, we included the concurrently present number of
syndrome components as a continuous independent var-
iable in the multiple regression models.
Results
Table 1 contains the characteristics of the study sample.
The metabolic syndrome was present in 19.7% of all par-
ticipants and it was clearly more common among women
than men. High blood pressure was by far the most prev-
alent single component of the metabolic syndrome and
affected about 75% of all participants. Among subjects
with high blood pressure according to the ATPIII defini-
tion of the metabolic syndrome, 80% (415 out of 519)
had hypertension defined by blood pressure higher than
or equal to 140/90 mmHg or using anti-hypertensive
drugs. Men had a higher predicted risk of coronary heart
disease, according to Framingham prediction score. Car-
diac abnormalities were also fairly common in this sam-
ple and heart failure stage C affected 8.4% of females and
5.2% of males.
Concurrence of various components of the metabolic syn-
drome increased significantly with age and was more fre-
quently found in women. It was also significantly and
strongly associated with predicted 10-year risk of coronary
heart disease by the Framingham score.BMC Cardiovascular Disorders 2007, 7:17 http://www.biomedcentral.com/1471-2261/7/17
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Table 1: Characteristics of the study sample and prevalence of the metabolic syndrome and its defining features.
Women n = 416 Men n = 268
Age (years), mean (standard deviation) 61 (10) 62 (11)
Metabolic syndrome, n(%) 97 (23.3) 38 (14.2)
Number of features of the metabolic syndrome, n(%)
0 59 (14.2) 35 (13.1)
1 123 (29.6) 106 (39.6)
High blood pressure 92 (60.9) 11 (23.9)
High triglycerides 4 (6.3) 11 (23.9)
Low HDL-cholesterol 20 (25.3) 5(12.5)
Waist circumference 5 (7.8) 0
High fasting serum glucose 2 (3.3) 3(7.9)
2 137 (32.9) 89 (33.2)
3 55 (13.2) 24 (9.0)
4–5 42 (10.1) 14 (5.2)
Features of the metabolic syndrome, n(%)
High blood pressure (≥ 130/85 mmHg) 307 (73.8) 212 (79.1)
High triglycerides (≥ 150 mg/dl) 90 (21.6) 79 (29.5)
Low HDL-cholesterol (< 50 mg/dl women; < 40 mg/dl men) 66 (15.9) 23 (8.6)
Waist circumference > 88 cm women or > 102 cm men 215 (51.7) 45 (16.8)
High fasting serum glucose (≥ 110 mg/dl) 60 (14.4) 55 (20.5)
Coronary heart disease, n(%) 34 (8.2) 30 (11.2)
10-year risk of CHD (FHS risk score)*
< 5% 104 (30.7) 20 (9.7)
5–10% 145 (43.3) 58 (28.2)
10–15% 57 (17.0) 57 (27.7)
≥ 15% 30 (9.0) 71 (34.5)
LVSD, n(%) 10 (2.4) 20 (7.5)
LV diameter/height (mm/m), median (interquartile range) 30.1 (28.3–32.2) 29.1 (27.1–31.2)
LV mass/height (g/m), median (interquartile range) 103.7 (86.4–124.5) 112.5 (92.0–136.1)
LV mass/height2.7 (g/m2.7), median (interquartile range) 50.2 (40.8–61.0) 46.6 (37.7–57.2)
LV mass/FFM (g/kg), median (interquartile range) 3.97 (3.28–4.71) 3.51 (2.87–4.20)
Posterior wall/height (mm/m), median (interquartile range) 5.5 (5.1–6.2) 5.4 (4.8–6.0)
Interventricular septum/height (mm/m), median (interquartile range) 6.2 (5.6–6.8) 5.9 (5.4–6.6)
Relative wall thickness, median (interquartile range) 0.37 (0.33–0.42) 0.37 (0.33–0.41)
Left atrium/height (mm/m), median (interquartile range) 23.0 (21.3–24.8) 21.9 (20.5–23.7)
E wave/A wave (peak velocity), median (interquartile range) 0.95 (0.78–1.20) 0.94 (0.77–1.16)
Diastolic dysfunction, n(%) 97 (24.1) 74 (29.0)
Stage C of heart failure (symptomatic cardiac dysfunction), n(%) 35 (8.4) 14 (5.2)
*Valid values available for 541 participants.
CHD, coronary heart disease; FHS, Framingham Heart Study; LVSD, left ventricular systolic dysfunction; LV, left ventricle; 
FFM, fat-free massBMC Cardiovascular Disorders 2007, 7:17 http://www.biomedcentral.com/1471-2261/7/17
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There was a positive association between the degree of the
metabolic syndrome – assessed as number of concurrently
present components – and parameters of cardiac structure
and function, with a consistent and statistically significant
trend for all cardiac variables considered (Table 2). These
analyses were adjusted for age and gender. Parameters of
left ventricular geometry patterns, left atrial diameter and
diastolic dysfunction maintained this trend when taking
into account the 10-year predicted risk of coronary heart
disease by the Framingham score as an independent vari-
able, while LVSD did not (Table 3). Of note, the associa-
tion between stage C of heart failure and degree of
metabolic syndrome showed borderline significance.
Since the Framingham risk score can be computed only
for subjects aged less than 75 years and with no coronary
heart disease, the data on Table 3 refer only to 541 sub-
jects who fulfil these criteria. In order to assess whether
the difference between adjusting for age and gender
(Table 2) and adjusting for Framingham risk score (Table
3, in bold font) was explained by adjustment to different
covariates or by the subsample that was being used, we
also present data on this subsample (aged < 75 years, with
no coronary heart disease) adjusting only for age and gen-
der (Table 3, square brackets). The difference in the asso-
ciation between LVSD and number of features of the
metabolic syndrome was in fact due to adjustment for
Framingham risk score. The adjusted prevalence of LVSD
increased with increasing degree of metabolic syndrome,
but the association was not statistically significant when
adjusting for Framingham risk score.
The prevalence of left ventricular diastolic dysfunction,
and the mean left ventricular mass, left ventricular diame-
ter and left atrial diameter increased significantly with the
number of features of the metabolic syndrome when
additionally adjusting for systolic blood pressure as a con-
tinuous variable (Figure 1).
Discussion
In this study, we found an association between systolic
and diastolic dysfunction and the degree of metabolic
syndrome, with the frequency and/or the severity of systo-
lic and diastolic dysfunction increasing with the number
of features of the metabolic syndrome. Importantly, early
asymptomatic stages of cardiac dysfunction increased pro-
gressively with the severity of the metabolic syndrome,
independently of systolic blood pressure.
Previous studies demonstrated an association between
insulin resistance and heart failure [29]. In a nested case-
Table 2: Cardiac structure and function parameters according to number of features of metabolic syndrome, adjusted for age and 
gender.
Number of features of the metabolic syndrome
0 1 2 3 4–5 p (trend)
n = 94 n = 229 n = 226 n = 79 n = 56
Adjusted prevalence 
(95%CI)
Stage C of heart failure 2.4 (0.6–9.2) 4.0 (2.2–7.3) 4.7 (2.7–8.3) 8.1 (4.0–15.7) 10.5 (5.1–20.5) 0.007
LVSD 0.0 (0.0-0.0) 2.7 (1.3–5.6) 3.0 (1.5–6.0) 2.7 (0.8–8.5) 7.1 (2.9–16.6) 0.02
Diastolic dysfunction 20.8 (13.4–30.6) 23.9 (18.7–30.1) 25.7 (20.3–32.0) 30.2 (20.9–41.6) 36.0 (24.1–49.9) 0.03
Coronary heart disease 3.6 (1.2–10.6) 6.5 (4.0–10.5) 8.1 (5.2–12.4) 10.0 (5.2–18.6) 18.4 (10.3–30.7) 0.002
Adjusted mean 
(95%CI)
LV diameter/height 
(mm/m)
29.4 (28.8–30.0) 29.7 (29.3–30.1) 29.9 (29.5–30.3) 29.9 (29.2–30.6) 30.9 (30.1–31.6) 0.008
LV mass/height (g/m) 100.1 (93.5–106.8) 109.0 (104.8–113.3) 113.8 (109.7–118.0) 120.0 (112.8–127.2) 129.9 (121.3–138.5) < 0.001
LV mass/height2.7 
(g/m2.7)
45.9 (42.8–49.1) 49.7 (47.7–51.7) 52.1 (50.1–54.1) 54.5 (51.1–58.0) 59.4 (55.3–63.4) < 0.001
LV mass/FFM (g/kg) 3.66 (3.44–3.89) 3.92 (3.78–4.07) 3.97 (3.82–4.11) 4.08 (3.83–4.33) 4.39 (4.09–4.68) < 0.001
Posterior wall/height 
(mm/m)
5.3 (5.2–5.5) 5.5 (5.4–5.6) 5.6 (5.5–5.7) 5.8 (5.6–6.0) 5.8 (5.6–6.1) < 0.001
Interventricular 
septum/height (mm/m)
5.8 (5.6–6.0) 6.1 (5.9–6.2) 6.2 (6.1–6.4) 6.4 (6.2–6.6) 6.6 (6.4–6.9) < 0.001
Relative wall thickness 0.37 (0.35–0.38) 0.38 (0.37–0.38) 0.38 (0.37–0.39) 0.39 (0.37–0.40) 0.38 (0.36–0.40) 0.05
Left atrium/height 
(mm/m)
22.0 (21.4–22.6) 22.3 (22.0–22.7) 23.5 (23.1–23.8) 23.5 (22.9–24.1) 24.1 (23.4–24.8) < 0.001
E wave/A wave 
(peak velocity)
1.06 (1.00–1.12) 1.04 (1.00–1.08) 0.97 (0.93–1.01) 0.91 (0.85–0.98) 0.94 (0.86–1.02) < 0.001
CI, confidence interval; LVSD, left ventricular systolic dysfunction; LV, left ventricle; FFM, fat-free mass.BMC Cardiovascular Disorders 2007, 7:17 http://www.biomedcentral.com/1471-2261/7/17
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control study in Swedish elderly men [7], factors associ-
ated with insulin resistance (heart rate, serum proinsulin,
a high proportion of dihomogammalinolenic acid in
serum cholesterol esters and hypophosphataemia) were
associated with left ventricular systolic dysfunction after
20-year follow-up, independently of ischaemic heart dis-
ease, hypertension and medications. In the Strong Heart
Study [30], American Indians with the metabolic syn-
drome had greater left ventricular dimension, mass, rela-
tive wall thickness and left atrial diameter, a higher
prevalence of left ventricular hypertrophy, and lower ejec-
tion fraction and mitral E/A ratio. In a cross-sectional
analysis within the ARIC Study [31], the degree of meta-
bolic syndrome clustering was strongly related to LV mass
and wall thickness in black women and men. This associ-
ation was not observed for chamber size, suggesting that
there was a specific effect on myocardial thickening but
not dilation. Our study describes a population-based sam-
ple of Caucasian men and women, in a country with low
prevalence of ischaemic heart disease and high prevalence
of hypertension and stroke. Recently we showed that the
prevalence of heart failure is not lower than in other west-
ern countries [16]. We thoroughly characterised partici-
pants in terms of cardiac structure and function. The
statistical association with increasing number of features
of metabolic syndrome can be explained by the increasing
impact of multiple independent risk factors and does not
necessarily mean that there is synergism. Given the ten-
dency of individual factors to aggregate, the prevalence of
each component in isolation was very low, except for high
blood pressure as shown in Table 1. Therefore, it was not
possible to estimate the sole effect of each factor, in com-
parison with the absence of all factors. This would be nec-
essary to truly assess an interaction between individual
factors. Given that increasing concurrence of factors of the
metabolic syndrome might only be a proxy for higher
blood pressure, it is a strength of this study that the
reported associations were not explained by blood pres-
sure level.
From the clinical and public health perspective, it has
been questioned whether metabolic syndrome improves
Table 3: Cardiac structure and function parameters according to degree of metabolic syndrome, adjusted for 10-year risk of CHD 
predicted by Framingham Heart Study risk score, in 541 participants aged < 75 years and with no CHD (bold font).
Number of features of the metabolic syndrome
01 2 34 – 5
n = 86 n = 185 n = 176 n = 61 n = 33 p (trend)
Adjusted 
prevalence 
(95%CI)
Stage C of heart 
failure
2.4 (0.6–9.3)
[3.2 (0.8–11.9)]
3.3 (1.5–7.1)
[3.0 (1.3–6.8)]
5.7 (3.1–10.2)
[5.3 (2.7–9.9)]
11.3 (5.4–22.1)
[8.9 (4.0–18.7)]
11.6 (4.1–28.6)
[6.8 (2.2–18.9)]
0.007
0.06
LVSD 0.0 (0.0–0.0)
[0.0 (0.0–0.0)]
3.1 (1.3–6.8)
[2.5 (1.0–6.3)]
2.0 (0.7–5.3)
[1.8 (0.6–5.2)]
1.2 (0.2–8.4)
[1.5 (0.2–9.9)]
7.3 (2.3–20.5)
[9.1 (3.1–23.9)]
0.19
0.06
Diastolic 
dysfunction
18.3 (11.2–28.5)
[18.3 (11.2–28.5)]
24.1 (18.4–30.9)
[23.9 (18.1–30.9)]
22.7 (16.9–29.6)
[22.8 (17.0–30.0)]
31.1 (20.7–43.9)
[32.4 (21.7–45.3)]
39.1 (23.5–57.3)
[41.0 (25.4–58.6)]
0.04
0.02
Adjusted mean 
(95%CI)
LV diameter/
height (mm/m)
29.1 (28.4–29.7)
[29.2 (28.5–29.8)]
29.4 (28.9–29.8)
[29.4 (29.0–29.9)]
29.6 (29.2–30.1)
[29.7 (29.2–30.1)]
29.7 (29.0–30.5)
[29.6 (28.9–30.3)]
31.1 (30.1–32.2)
[30.9 (29.9–31.9)]
0.003
0.02
LV mass/height 
(g/m)
98.3 (92.1–104.5)
[97.4 (91.3–103.6)]
106.3 (102.1–110.4)
[106.8 (102.6–111.0)]
109.4 (105.2–113.5)
[111.4 (107.2–115.5)]
110.9 (103.8–118.1)
[115.6 (108.5–122.7)]
124.3 (114.3–134.3)
[131.8 (122.2–141.4)]
< 0.001
< 0.001
LV mass/height2.7 
(g/m2.7)
43.5 (40.6–46.5)
[44.6 (41.7–47.5)]
47.7 (45.7–49.6)
[48.7 (46.7–50.7)]
49.8 (47.8–51.7)
[50.9 (49.0–52.9)]
51.4 (48.0–54.8)
[52.1 (48.8–55.4)]
58.8 (54.0–63.5)
[59.5 (54.9–64.0)]
< 0.001
< 0.001
LV mass/FFM 
(g/kg)
3.47 (3.25–3.69)
[3.58 (3.37–3.79)]
3.75 (3.60–3.89)
[3.85 (3.70–3.99)]
3.79 (3.64–3.93)
[3.88 (3.74–4.02)]
3.92 (3.67–4.17)
[3.92 (3.68–4.16)]
4.41 (4.06–4.76)
[4.37 (4.04–4.70)]
< 0.001
< 0.001
Posterior wall/
height (mm/m)
5.2 (5.0–5.4)
[5.3 (5.1–5.5)]
5.4 (5.3–5.6)
[5.5 (5.4–5.6)]
5.5 (5.4–5.6)
[5.6 (5.5–5.7)]
5.7 (5.4–5.9)
[5.7 (5.5–5.9)]
5.9 (5.6–6.2)
[5.9 (5.7–6.2)]
< 0.001
< 0.001
Interventricular 
septum/height 
(mm/m)
5.6 (5.4–5.8)
[5.7 (5.5–5.9)]
6.0 (5.8–6.1)
[6.0 (5.9–6.2)]
6.1 (6.0–6.3)
[6.2 (6.1–6.4)]
6.3 (6.0–6.5)
[6.3 (6.1–6.6)]
6.4 (6.1–6.8)
[6.5 (6.2–6.8)]
< 0.001
< 0.001
Relative wall 
thickness
0.36 (0.35–0.38)
[0.37 (0.35–0.38)]
0.37 (0.36–0.38)
[0.38 (0.37–0.39)]
0.37 (0.36–0.38)
[0.38 (0.37–0.39)]
0.38 (0.36–0.40)
[0.39 (0.37–0.40)]
0.39 (0.36–0.41)
[0.39 (0.37–0.41)]
0.07
0.07
Left atrium/height 
(mm/m)
21.4 (20.9–22.0)
[21.8 (21.3–22.3)]
21.9 (21.5–22.3)
[22.2 (21.8–22.5)]
23.1 (22.8–23.5)
[23.3 (23.0–23.7)]
23.5 (22.8–24.1)
[23.4 (22.8–24.0)]
23.9 (23.0–24.7)
[23.7 (22.9–24.5)]
< 0.001
< 0.001
E wave/A wave 
(peak velocity)
1.09 (1.02–1.16)
[1.04 (0.98–1.10)]
1.05 (1.00–1.09)
[1.01 (0.97–1.05)]
1.01 (0.97–1.06)
[0.96 (0.92–1.01)]
0.94 (0.87–1.02)
[0.91 (0.84–0.98)]
1.00 (0.89–1.11)
[0.96 (0.86–1.06)]
0.01
0.004
Data in square brackets are adjusted for age and gender, in the same subsample of participants aged < 75 years and with no CHD (n = 541). CHD, 
coronary heart disease; CI, confidence interval; LVSD, left ventricular systolic dysfunction; LV, left ventricle; FFM, fat-free mass.BMC Cardiovascular Disorders 2007, 7:17 http://www.biomedcentral.com/1471-2261/7/17
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cardiovascular risk prediction, beyond previously used
tools such as the Diabetes Predicting Model for type 2 dia-
betes or Framingham risk score for coronary heart disease
[12-14], [32-34]. Some studies have assessed whether the
metabolic syndrome predicts the risk of cardiovascular
diseases or a surrogate such as subclinical atherosclerosis
[35,36]. In the majority of these studies, however, the out-
come with which the metabolic syndrome was to be
related was atherosclerotic vascular disease, either coro-
nary heart disease alone or stroke. When assessing cardiac
structure and function, one must keep in mind that coro-
nary heart disease is not the only determinant of systolic
and diastolic dysfunction. When adjusting for Framigham
risk score, we are in fact assessing the effect of features of
the metabolic syndrome not considered in the score
(obesity and triglycerides) as well as abnormalities of car-
bohydrate metabolism that are not severe enough to
establish the diagnosis of diabetes (impaired fasting glu-
cose). Moreover, if there is increasing insulin resistance
with increasing degree of metabolic syndrome, there may
additionally be a mitogenic stimulus for cardiac hypertro-
phy. It is not very surprising, therefore, that particularly LV
mass, wall thickness and, probably in consequence, atrial
diameter were the cardiac parameters that remained sig-
nificantly associated with increasing severity of metabolic
syndrome even when adjusting for the Framingham risk
score.
In comparison with previous studies, this study addition-
ally shows that the association is not fully explained by
the level of blood pressure, and that the metabolic syn-
drome may help predict an increased cardiovascular risk
beyond that predicted by the more frequently used tool
Framingham risk score.
Adjusted prevalence of stage C of heart failure (HF), left ventricular systolic dysfunction (LVSD) and left ventricular diastolic  dysfunction (LVDD) according to number of features of the metabolic syndrome, estimated by multiple linear regression  (upper panel) Figure 1
Adjusted prevalence of stage C of heart failure (HF), left ventricular systolic dysfunction (LVSD) and left ventricular diastolic 
dysfunction (LVDD) according to number of features of the metabolic syndrome, estimated by multiple linear regression 
(upper panel). Adjusted mean of left ventricular (LV) mass, LV diameter and left atrial (LA) diameter, all indexed to height, 
according to number of features of the metabolic syndrome estimated by multiple logistic regression (lower panel). In each 
chart, three models are presented: adjusting for age and gender (blue line), adjusting for the predicted 10-year risk of coronary 
heart disease by the Framingham risk score (orange) and adjusting for age, gender and systolic blood pressure (green). The 
dotted lines represent 95% confidence intervals of estimates. P values are for linear trend and were estimated by running the 
same models with the number of features of the metabolic syndrome as a continuous variable.
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The main limitation of the present study is the relatively
small sample size expectedly leading to few outcomes in
certain categories, such as left ventricular systolic dysfunc-
tion, and weakening assessment of interactions between
the factors of the metabolic syndrome, which would be
most relevant in trying to document synergistic effects.
The cross-sectional design is also not the ideal approach to
assess causality. Advanced cachectic heart failure patients
have a particularly high fatality rate and are most likely
underrepresented in a dwellers sample like ours (length
bias) and less likely to participate if selected (due to func-
tional impairment). An overestimation of the strength of
the association with heart failure could also result from
the "reverse epidemiology" of cardiovascular risk factors
[37], because once overt heart failure is installed obesity,
hypertension and hypercholesterolaemia are associated
with increased survival. The assessment of early stages of
the outcome up to overt heart failure instead of the final
outcome should avoid this bias and is a strength of our
study. Restriction to participants who do not take any
antihypertensive drug, statin, insulin or antidiabetic
would result in a probably differential reduction of the
sample size to 413 participants, either because those that
are medicated have more "severe" metabolic syndrome or
on the contrary because they are more health concerned
and under closer surveillance. The assessment of the asso-
ciation between the metabolic syndrome and cardiac
structure and function in this group would be severely
biased (selection bias). Thus, we can only speculate that if
medications attenuate the cardiovascular effects of the
metabolic syndrome, our estimate of effect is likely con-
servative.
Conclusion
In summary, symptomatic heart failure and several car-
diac structural and functional abnormalities regardless of
symptoms increased progressively with increasing degree
of metabolic syndrome. This association was independent
of 10-year predicted risk of coronary heart disease by
Framingham risk score for indirect indices of diastolic
dysfunction but not systolic dysfunction.
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